Document is current
Any future updates will be listed below
-
Authors
Bonnardel, Eline
Prevel, Renaud
Campagnac, Marilyne
Dubreuil, Marielle
Marthan, Roger
Berger, Patrick
Dupin, Isabelle https://orcid.org/0000-0002-4992-9625
-
Funding
Funding for this research was provided by:
INSERM (no number)
Universite de Bordeaux (no number)
Aquitaine Science Transfert (no number)
- License Information
-
More Information
Article History
Received: 3 April 2019
Accepted: 2 September 2019
First Online: 14 September 2019
Ethics approval
: All animal studies were made according to European and French directives about vertebrate animals protection use for animal experiments. Agreement was obtained from French authorities (number A33–063-907) and all the protocols used were approved by the local ethics committee (“Comité d’éthique regional d’Aquitaine”, protocol number: 2018030715546195–APAFiS # 13957).
: Not applicable.
: Dr. Berger reports grants from Nycomed, grants from Takeda, grants from Fondation du Souffle–Fonds de dotation Recherche en Santé Respiratoire, during the conduct of the study; grants and personal fees from Novartis, personal fees and non-financial support from Chiesi, grants, personal fees and non-financial support from Boehringer Ingelheim, personal fees and non-financial support from AstraZeneca, personal fees and non-financial support from Sanofi, personal fees from Menarinni, personal fees from TEVA, outside the submitted work. In addition, Dr. Berger and Dr. Dupin have a patent (EP N°15152886.6 i.e. New compositions and methods of treating and/or preventing Chronic Obstructive Pulmonary Disease) pending.
